US4853332A
(en)
|
1982-10-19 |
1989-08-01 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
|
FI82266C
(en)
|
1982-10-19 |
1991-02-11 |
Cetus Corp |
Process for Preparation of IL-2 Mutein
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
US4530787A
(en)
|
1984-03-28 |
1985-07-23 |
Cetus Corporation |
Controlled oxidation of microbially produced cysteine-containing proteins
|
US4572798A
(en)
|
1984-12-06 |
1986-02-25 |
Cetus Corporation |
Method for promoting disulfide bond formation in recombinant proteins
|
CA1340265C
(en)
|
1985-01-18 |
1998-12-15 |
Kirston E. Koths |
Oxidation resistant muteins
|
US5116943A
(en)
|
1985-01-18 |
1992-05-26 |
Cetus Corporation |
Oxidation-resistant muteins of Il-2 and other protein
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
US4766106A
(en)
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
US4816440A
(en)
|
1985-09-26 |
1989-03-28 |
Cetus Corporation |
Stable formulation of biologically active proteins for parenteral injection
|
US5425940A
(en)
|
1986-04-09 |
1995-06-20 |
Cetus Oncology Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
US4863727A
(en)
|
1986-04-09 |
1989-09-05 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
US5098702A
(en)
|
1986-04-09 |
1992-03-24 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
US4894226A
(en)
|
1986-11-14 |
1990-01-16 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
|
AU3285989A
(en)
|
1987-11-25 |
1989-06-14 |
Cetus Corporation |
Treatment of infections caused by a primary immunodeficiency with interleukin-2
|
US5066489A
(en)
|
1988-03-28 |
1991-11-19 |
Cetus Corporation |
Combination therapy of IL-2 and DTIC for the treatment of melanoma
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
US5153310A
(en)
|
1989-02-28 |
1992-10-06 |
Du Pont Merck Pharmaceutical Company |
Il-2 analogs containing n-linked glycosylation sites
|
NZ234674A
(en)
|
1989-08-02 |
1992-02-25 |
Seragen Inc |
Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
|
US5660827A
(en)
|
1992-03-05 |
1997-08-26 |
Board Of Regents, The University Of Texas System |
Antibodies that bind to endoglin
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
WO1997003703A1
(en)
|
1995-07-21 |
1997-02-06 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
|
DK0808367T3
(en)
*
|
1995-02-10 |
2007-11-05 |
Millennium Pharm Inc |
Vascular mucosal dressings and their use
|
US20040115128A1
(en)
|
1995-09-08 |
2004-06-17 |
Schnitzer Jan E. |
Targeting endothelium for tissue-specific delivery of agents
|
EP1442750B1
(en)
|
1997-11-20 |
2012-08-01 |
Vical Incorporated |
Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
|
JP2001523480A
(en)
|
1997-11-20 |
2001-11-27 |
バイカル インコーポレイテッド |
Treatment of cancer with cytokine-expressed polynucleotides and their compositions
|
US6232287B1
(en)
|
1998-03-13 |
2001-05-15 |
The Burnham Institute |
Molecules that home to various selected organs or tissues
|
US6455677B1
(en)
|
1998-04-30 |
2002-09-24 |
Boehringer Ingelheim International Gmbh |
FAPα-specific antibody with improved producibility
|
DZ2788A1
(en)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Selective IL-2 agonists and antagonists.
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
US7138103B2
(en)
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
ES2207278T3
(en)
|
1998-07-28 |
2004-05-16 |
Micromet Ag |
HETEROMINICBODIES.
|
US6294349B1
(en)
|
1999-03-01 |
2001-09-25 |
University Of Mississippi Medical Ctr. |
Method of diagnosing and monitoring malignant breast carcinomas
|
US6348192B1
(en)
|
1999-05-11 |
2002-02-19 |
Bayer Corporation |
Interleukin-2 mutein expressed from mammalian cells
|
CZ305123B6
(en)
|
1999-10-04 |
2015-05-13 |
Novartis Vaccines And Diagnostics, Inc. |
Process for preparing liquid pharmaceutical composition
|
AU2001227966A1
(en)
|
2000-01-20 |
2001-07-31 |
Chiron Corporation |
Methods for treating tumors
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
US6579521B2
(en)
|
2000-10-20 |
2003-06-17 |
Chiron Corporation |
Methods of therapy for HIV infection
|
CA2449517A1
(en)
|
2001-06-08 |
2002-12-19 |
Utah Ventures Ii, L.P. |
Tissue-specific endothelial membrane proteins
|
EP1476180A4
(en)
|
2001-08-13 |
2005-04-20 |
Univ Southern California |
Interleukin-2 mutants with reduced toxicity
|
US20020187512A1
(en)
|
2001-09-10 |
2002-12-12 |
Nagem Ronaldo Alves Pinto |
Crystal structure of human interleukin-22
|
US7186804B2
(en)
|
2001-12-04 |
2007-03-06 |
Emd Lexigen Research Center Corp. |
IL-2 fusion proteins with modulated selectivity
|
DK1576112T3
(en)
|
2002-01-18 |
2012-06-25 |
Zymogenetics Inc |
CYTOKIN RECEPTOR ZCYTOR17 MULTIMIZER
|
ATE466085T1
(en)
|
2002-09-09 |
2010-05-15 |
Hanall Pharmaceutical Co Ltd |
PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDES
|
EP3299393A1
(en)
|
2002-11-08 |
2018-03-28 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
JP4511943B2
(en)
|
2002-12-23 |
2010-07-28 |
ワイス エルエルシー |
Antibody against PD-1 and use thereof
|
US20070202097A1
(en)
*
|
2003-03-10 |
2007-08-30 |
Krissansen Geoffrey W |
Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof
|
US7569215B2
(en)
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
DE602004031341D1
(en)
|
2003-07-21 |
2011-03-24 |
Transgene Sa |
MULTIFUNCTIONAL CYTOKINE
|
DK1944318T3
(en)
|
2003-07-21 |
2011-06-14 |
Transgene Sa |
Multifunctional cytokines
|
KR100632985B1
(en)
|
2003-07-26 |
2006-10-11 |
메덱스젠 주식회사 |
A method of improving efficacy of biological response-modifying proteins and the example muteins
|
US20050069521A1
(en)
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
US8454963B2
(en)
|
2003-11-13 |
2013-06-04 |
Musc Foundation For Research Development |
Tissue targeted complement modulators
|
EP1709196A4
(en)
|
2003-12-22 |
2008-10-29 |
Novartis Vaccines & Diagnostic |
Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
|
PT2177537E
(en)
|
2004-01-09 |
2011-12-13 |
Pfizer |
Antibodies to madcam
|
RU2006135112A
(en)
|
2004-03-05 |
2008-04-10 |
Чирон Корпорейшн (Us) |
IN VITRO TEST SYSTEM FOR FORECASTING PATIENT RESISTANCE TO THERAPEUTIC MEDICINES
|
CA2566363C
(en)
|
2004-05-19 |
2014-12-16 |
Avidex Ltd |
High affinity ny-eso t cell receptor
|
WO2005117977A2
(en)
|
2004-06-02 |
2005-12-15 |
Sidney Kimmel Cancer Center |
Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
|
US20070014765A1
(en)
|
2005-01-27 |
2007-01-18 |
Chiron Corporation |
Methods for treating renal cell carcinoma
|
BRPI0607351A2
(en)
|
2005-02-15 |
2009-09-01 |
Novartis Vaccines & Diagnostic |
methods for treating lymphomas employing a combination of chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody
|
WO2006096461A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
|
KR101339628B1
(en)
|
2005-05-09 |
2013-12-09 |
메다렉스, 인코포레이티드 |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
NZ581779A
(en)
|
2005-05-17 |
2011-09-30 |
Univ Connecticut |
Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex
|
DE602006017373D1
(en)
*
|
2005-07-08 |
2010-11-18 |
Pfizer Ltd |
MADCAM ANTIBODY
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
PT1999154E
(en)
|
2006-03-24 |
2013-01-24 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
NZ572773A
(en)
|
2006-06-06 |
2011-11-25 |
Crucell Holland Bv |
Human binding molecules having killing activity against staphylococci and uses thereof
|
WO2008003473A2
(en)
|
2006-07-06 |
2008-01-10 |
Merck Patent Gmbh |
Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
|
US8470323B2
(en)
|
2007-01-09 |
2013-06-25 |
The Trustees Of The University Of Pennsylvania |
Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display
|
WO2008097439A2
(en)
|
2007-02-07 |
2008-08-14 |
The Trustees Of The University Of Pennsylvania |
Anti-autoimmune antibodies for treatment of pemphigus
|
EP3269384A1
(en)
|
2007-03-07 |
2018-01-17 |
Uti Limited Partnership |
Compositions and methods for the prevention and treatment of autoimmune conditions
|
WO2008124858A2
(en)
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
US20080260820A1
(en)
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
WO2009002380A2
(en)
|
2007-06-26 |
2008-12-31 |
The Trustees Of The University Of Pennsylvania |
Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
|
WO2009061853A2
(en)
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
EP2225397A4
(en)
|
2007-11-28 |
2011-08-17 |
Univ Montreal |
Pd-1 modulation and uses thereof
|
DE102008023820A1
(en)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
An agent for the treatment and / or prophylaxis of an autoimmune disease and for the production of regulatory T cells
|
JP2012501670A
(en)
|
2008-09-12 |
2012-01-26 |
アイシス・イノベーション・リミテッド |
PD-1-specific antibodies and uses thereof
|
CA2736816C
(en)
|
2008-09-12 |
2018-05-22 |
Isis Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
CN107056951A
(en)
|
2008-10-02 |
2017-08-18 |
阿帕特夫研究和发展有限公司 |
CD86 antagonist Mutiple Targets associated proteins
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
MX2011004193A
(en)
|
2008-10-21 |
2011-05-24 |
Merck Patent Gmbh |
Cancer treatments with radiation and immunocytokines.
|
AU2010206840B2
(en)
|
2009-01-21 |
2015-02-05 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
WO2010117423A2
(en)
|
2009-03-31 |
2010-10-14 |
Duke University |
A METHOD FOR TREATING A PATIENT HAVING OR AT RISK FOR DEVELOPING A DISORDER ASSOCIATED WITH DECREASED EXPRESSION OF ß2 ADRENERGIC RECEPTORS OR NEED FOR INCREASED ß2 ADRENERGIC RECEPTOR ACTIVITY
|
NZ714757A
(en)
|
2009-08-14 |
2018-07-27 |
Us Gov Health & Human Services |
Use of il-15 to increase thymic output and to treat lymphopenia
|
CU23734A1
(en)
|
2009-11-27 |
2011-11-15 |
Centro Inmunologia Molecular |
IMMUNOMODULATOR POLIPEPTIDES DERIVED FROM IL-2 WITH ANTIGONIST ACTIVITY OF THIS CITOCINE USED IN CANCER THERAPY AND CHRONIC INFECTIOUS DISEASES
|
AU2010343056A1
(en)
|
2009-12-29 |
2012-08-02 |
Emergent Product Development Seattle, Llc |
Ron binding constructs and methods of use thereof
|
NZ602294A
(en)
|
2010-03-10 |
2015-04-24 |
Genmab As |
Monoclonal antibodies against c-met
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
WO2011110604A1
(en)
|
2010-03-11 |
2011-09-15 |
Ucb Pharma, S.A. |
Pd-1 antibody
|
WO2012058768A1
(en)
|
2010-11-05 |
2012-05-10 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
PT2637694T
(en)
|
2010-11-12 |
2021-05-05 |
Nektar Therapeutics |
Conjugates of an il-2 moiety and a polymer
|
CU23923B1
(en)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
POLYPEPTIDES DERIVED FROM IL-2 WITH AGONIST ACTIVITY
|
WO2012088446A1
(en)
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
TWI666027B
(en)
|
2011-02-10 |
2019-07-21 |
羅齊克雷雅公司 |
Mutant interleukin-2 polypeptides
|
US20120207733A1
(en)
|
2011-02-14 |
2012-08-16 |
Allergan, Inc. |
Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases
|
WO2012119093A1
(en)
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
CA2828811C
(en)
|
2011-03-03 |
2021-09-21 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
EP2683395B1
(en)
|
2011-03-11 |
2018-08-01 |
Assistance Publique - Hôpitaux de Paris |
Use of low dose il-2 for treating type 1 diabetes
|
ES2811624T3
(en)
|
2011-03-11 |
2021-03-12 |
Hopitaux Paris Assist Publique |
IL-2 Dosage Regimen to Treat Systemic Lupus Erythematosus
|
EA201892619A1
(en)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
|
WO2012163519A1
(en)
|
2011-05-27 |
2012-12-06 |
Dutalys |
Antibodies with improved folding stability
|
CA2840409A1
(en)
|
2011-06-28 |
2013-01-03 |
Whitehead Institute For Biomedical Research |
Using sortases to install click chemistry handles for protein ligation
|
EP2742953B1
(en)
|
2011-08-11 |
2021-09-22 |
ONO Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising pd-1 agonist
|
US20140248372A1
(en)
|
2011-09-19 |
2014-09-04 |
Emory University |
Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
|
BR112014010580B1
(en)
|
2011-11-04 |
2021-01-12 |
Zymeworks, Inc. |
isolated heteromultimeric fc construct, composition, use of an isolated heteromultimeric fc construct, nucleic acid composition and method for expressing the isolated heteromultimeric fc construct
|
EP2780364A2
(en)
|
2011-11-18 |
2014-09-24 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
CN110078818B
(en)
|
2012-04-27 |
2023-12-29 |
诺和诺德股份有限公司 |
Human CD30 ligand antigen binding proteins
|
WO2013177187A2
(en)
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
|
WO2013189516A1
(en)
|
2012-06-18 |
2013-12-27 |
Apeiron Biologics Ag |
Method for treating a gd2 positive cancer
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
CA2876293C
(en)
|
2012-06-27 |
2023-10-10 |
Arthrogen B.V. |
Combination for treating an inflammatory disorder
|
WO2014012082A2
(en)
|
2012-07-13 |
2014-01-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design an constructs
|
CN103566377A
(en)
|
2012-07-18 |
2014-02-12 |
上海博笛生物科技有限公司 |
Targeted immunotherapy for cancer
|
MY175687A
(en)
|
2012-08-07 |
2020-07-06 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
JP6174710B2
(en)
|
2012-12-05 |
2017-08-02 |
ナショナル チュン シン ユニバーシティ |
Chemokine-cytokine fusion protein and use thereof
|
WO2014100014A1
(en)
|
2012-12-17 |
2014-06-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Super-2 complexes with antibody to augment il-2 therapy
|
EP2950814A4
(en)
|
2013-01-31 |
2016-06-08 |
Univ Jefferson |
Pd-l1 and pd-l2-based fusion proteins and uses thereof
|
US20150259416A1
(en)
|
2014-03-12 |
2015-09-17 |
Biocrine Ab |
Methods for treating and/or limiting development of diabetes
|
US9546203B2
(en)
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
EA201890895A1
(en)
|
2013-03-15 |
2019-02-28 |
Зинджения, Инк. |
MULTIVALENT AND MONOVALENT MULTIS-SPECIFIC COMPLEXES AND THEIR APPLICATION
|
WO2014150600A2
(en)
|
2013-03-15 |
2014-09-25 |
Angelica Therapeutics, Inc. |
Modified toxins
|
AU2014262469B2
(en)
|
2013-05-10 |
2019-11-14 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
CN104395342B
(en)
|
2013-06-06 |
2017-07-04 |
合肥立方制药股份有限公司 |
The antibody in the anti-fibronectin ED B structures domain in people source and application thereof
|
WO2015066543A1
(en)
|
2013-11-01 |
2015-05-07 |
Board Of Regents, The University Of Texas System |
Targeting her2 and her3 with bispecific antibodies in cancerous cells
|
TWI681969B
(en)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
Human antibodies to pd-1
|
AU2015215001B2
(en)
|
2014-02-06 |
2019-08-15 |
F. Hoffmann-La Roche Ag |
Interleukin-2 fusion proteins and uses thereof
|
US10323077B2
(en)
|
2014-02-10 |
2019-06-18 |
Emory University |
Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
|
EP2918285A1
(en)
|
2014-03-11 |
2015-09-16 |
Université Pierre et Marie Curie (Paris 6) |
Interleukin-2 for treating food allergy
|
JP6935195B2
(en)
|
2014-03-11 |
2021-09-15 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
Protein containing binding region, effector region of Shiga toxin A subunit, and carboxy-terminal endoplasmic reticulum localization signal motif
|
CN106659757B
(en)
|
2014-04-24 |
2022-01-28 |
利兰斯坦福初级大学董事会 |
Superagonists, partial agonists and antagonists of interleukin 2
|
KR102496206B1
(en)
|
2014-06-11 |
2023-02-06 |
몰레큘러 템플레이츠, 인코퍼레이션. |
Protease-Cleavage Resistant, Shiga Toxin A Subunit Effector Polypeptides and Cell-Targeting Molecules Comprising The Same
|
EP2963057A1
(en)
|
2014-07-02 |
2016-01-06 |
Calypso Biotech SA |
Antibodies to IL-15
|
SG11201700514SA
(en)
|
2014-07-21 |
2017-02-27 |
Delinia Inc |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
AR101936A1
(en)
*
|
2014-07-31 |
2017-01-25 |
Amgen Res (Munich) Gmbh |
SPECIFIC BIESPECIFIC CHAIN ANTIBODY CONSTRUCTS SPECIFIED FOR OPTIMIZED CROSSED SPECIES
|
CN107074947B
(en)
|
2014-08-05 |
2021-04-09 |
马布奎斯特公司 |
Immunity agent binding to PD-1
|
MA40094B1
(en)
|
2014-08-06 |
2022-05-31 |
Univ Miami |
Interleukin-2/interleukin-2 alpha receptor fusion proteins and methods of use
|
PL3482766T3
(en)
|
2014-08-11 |
2020-11-16 |
Delinia, Inc. |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
CA2957717C
(en)
|
2014-08-12 |
2021-10-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
|
RU2710354C2
(en)
|
2014-08-29 |
2019-12-25 |
Ф.Хоффманн-Ля Рош Аг |
Combined therapy based on tumour-targeted immunocytokines containing variant il-2, and antibodies to human pd-l1
|
EP4006052A1
(en)
|
2014-10-23 |
2022-06-01 |
Singh Molecular Medicine, LLC |
Single domain antibodies directed against intracellular antigens
|
EP3233192B1
(en)
|
2014-12-15 |
2021-04-14 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
US10239942B2
(en)
|
2014-12-22 |
2019-03-26 |
Pd-1 Acquisition Group, Llc |
Anti-PD-1 antibodies
|
US20160206666A1
(en)
|
2014-12-22 |
2016-07-21 |
Synlogic, Inc. |
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
|
WO2016115168A1
(en)
|
2015-01-12 |
2016-07-21 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
SG10201913297TA
(en)
|
2015-03-13 |
2020-02-27 |
Cytomx Therapeutics Inc |
Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
|
CN107921122B
(en)
|
2015-04-08 |
2021-08-10 |
索伦托药业有限公司 |
Antibody therapeutics that bind to CD38
|
CA2975333A1
(en)
|
2015-04-22 |
2016-10-27 |
Curevac Ag |
Rna containing composition for treatment of tumor diseases
|
US20180154012A1
(en)
|
2015-05-05 |
2018-06-07 |
Rubicon Biotechnology Llc |
Cancer immunotherapeutic
|
GB201507908D0
(en)
|
2015-05-08 |
2015-06-24 |
Philogen Spa |
IL2 and TNF immunoconjugates
|
US9845345B2
(en)
|
2015-05-18 |
2017-12-19 |
Ab Initio Biotherapeutics, Inc. |
SIRP polypeptide compositions and methods of use
|
KR102526538B1
(en)
|
2015-06-10 |
2023-04-28 |
이뮤너티바이오, 인크. |
Modified NK-92 cells to treat cancer
|
CA3006224A1
(en)
|
2015-06-23 |
2016-12-29 |
Memorial Sloan-Kettering Cancer Center |
Novel pd-1 immune modulating agents
|
BR112017028315A2
(en)
|
2015-06-30 |
2018-09-04 |
Nanotics Llc |
sequestrant particle related compositions and methods
|
KR20180034619A
(en)
|
2015-07-29 |
2018-04-04 |
나노틱스 엘엘씨 |
Module compositions for eradicating soluble biomolecules and related methods
|
WO2017023780A1
(en)
|
2015-07-31 |
2017-02-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates for targeting cd56-positive tumors
|
TWI617319B
(en)
|
2015-09-01 |
2018-03-11 |
免疫功坊股份有限公司 |
Fusion proteins for treating pathological blood clots
|
EP3347056A4
(en)
|
2015-09-11 |
2019-02-27 |
The Board of Trustees of the Leland Stanford Junior University |
Biologically relevant orthogonal cytokine/receptor pairs
|
AU2016332725A1
(en)
|
2015-09-29 |
2018-03-22 |
Celgene Corporation |
PD-1 binding proteins and methods of use thereof
|
AU2016332900C1
(en)
|
2015-09-29 |
2024-02-01 |
Amgen Inc. |
ASGR inhibitors
|
MA45488A
(en)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
CELL CULTURE PROCESSES, KITS AND APPARATUS
|
MX2018004883A
(en)
|
2015-10-22 |
2018-08-01 |
Iltoo Pharma |
Pharmaceutical compositions of il-2.
|
US20170232070A1
(en)
|
2015-10-23 |
2017-08-17 |
Richard P. Junghans |
Combination Methods for Immunotherapy
|
WO2017070561A1
(en)
|
2015-10-23 |
2017-04-27 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
CA3003969A1
(en)
|
2015-11-06 |
2017-05-11 |
Orionis Biosciences Nv |
Bi-functional chimeric proteins and uses thereof
|
WO2017087789A1
(en)
|
2015-11-19 |
2017-05-26 |
Revitope Limited |
Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
|
US10597466B2
(en)
|
2015-12-02 |
2020-03-24 |
Fred Hutchinson Cancer Research Center |
Circular tandem repeat proteins
|
WO2017096262A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
BR112018003984A2
(en)
|
2015-12-09 |
2018-09-25 |
Hoffmann La Roche |
antibodies
|
WO2017102010A1
(en)
|
2015-12-17 |
2017-06-22 |
Biontech Rna Pharmaceuticals Gmbh |
Novel cytokine fusion proteins
|
CN108430511B
(en)
|
2015-12-21 |
2021-06-04 |
合肥立方制药股份有限公司 |
Drug design method, obtained drug and application thereof
|
US10889643B2
(en)
|
2016-01-11 |
2021-01-12 |
Universität Zürich |
Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
|
CA3008440A1
(en)
|
2016-01-11 |
2017-07-20 |
Universitat Zurich |
Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
|
WO2017123675A1
(en)
|
2016-01-11 |
2017-07-20 |
Synlogic, Inc. |
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
WO2017122180A1
(en)
|
2016-01-14 |
2017-07-20 |
Intrexon Actobiotics N.V. |
Compositions and methods for the treatment of type 1 diabetes
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
JP7220458B2
(en)
|
2016-02-05 |
2023-02-10 |
ワシントン・ユニバーシティ |
Compositions and methods for targeted cytokine delivery
|
ES2877568T3
(en)
|
2016-02-05 |
2021-11-17 |
Orionis Biosciences Nv |
Clec9A binding agents
|
US10888603B2
(en)
|
2016-02-12 |
2021-01-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating cancer cells expressing tumor-associated integrins
|
EP3211000B1
(en)
|
2016-02-25 |
2019-01-30 |
Provecs Medical GmbH |
Novel immunostimulating vector system
|
WO2017153402A1
(en)
|
2016-03-07 |
2017-09-14 |
Vib Vzw |
Cd20 binding single domain antibodies
|
CN109790545A
(en)
|
2016-03-10 |
2019-05-21 |
约翰·霍普金斯大学 |
Generate the method and therapeutical uses of the monomer diphtheria toxin fusion protein without aggregation
|
WO2017156720A1
(en)
|
2016-03-16 |
2017-09-21 |
谢彦晖 |
Glucocorticoid combined with polyethylene glycol-modified interleukin-2 for treating respiratory disease
|
ES2831852T3
(en)
|
2016-03-17 |
2021-06-09 |
Univ Oslo Hf |
Fusion proteins that target tumor associated macrophages to treat cancer
|
AU2017249694B2
(en)
|
2016-04-12 |
2019-10-03 |
Philogen S.P.A. |
Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (CAR)-T cell
|
ES2864095T3
(en)
|
2016-04-15 |
2021-10-13 |
Philogen Spa |
Non-glycosylated anti-tenascin antibody
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
JP7422480B2
(en)
|
2016-05-04 |
2024-01-26 |
アムジエン・インコーポレーテツド |
Interleukin-2 mutant protein for regulatory T cell proliferation
|
WO2017190684A1
(en)
|
2016-05-06 |
2017-11-09 |
王牧林 |
Interleukin combination and use thereof
|
GB201608192D0
(en)
|
2016-05-10 |
2016-06-22 |
Immunovia Ab |
Method, array and use thereof
|
EP3458485B1
(en)
|
2016-05-19 |
2021-12-29 |
The General Hospital Corporation |
Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
|
BR112018074152A8
(en)
|
2016-05-25 |
2023-01-31 |
Hoffmann La Roche |
METHODS FOR DETERMINING A DOSAGE REGIME, METHODS FOR TREATING AN INDIVIDUAL, METHOD FOR OPTIMIZING THERAPEUTIC TREATMENT, THERAPEUTIC AGENT AND NETWORK SYSTEM FOR DETERMINING AN EFFECTIVE DOSE OR DOSING REGIME FOR AN INDIVIDUAL BEING TREATED WITH A THERAPEUTIC AGENT
|
JP2019517577A
(en)
|
2016-05-27 |
2019-06-24 |
エトゥビクス コーポレーション |
Neoepitope vaccine composition and method of using the same
|
CA3026360A1
(en)
|
2016-06-03 |
2017-12-07 |
Etubics Corporation |
Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases
|
CN110234752A
(en)
|
2016-06-03 |
2019-09-13 |
埃特彼塞斯公司 |
For being related to the tumor vaccination of HER2/NEU and the composition and method of immunotherapy
|
CA3026342A1
(en)
|
2016-06-03 |
2017-12-07 |
Etubics Corporation |
Compositions and methods for tumor vaccination using prostate cancer-associated antigens
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
WO2017220704A1
(en)
|
2016-06-22 |
2017-12-28 |
David Klatzmann |
Genetically modified t lymphocytes
|
US11141463B2
(en)
|
2016-07-11 |
2021-10-12 |
The National Institute for Biotechnology in the Negev Ltd. |
Fusion proteins with extended serum half life
|
WO2018014008A1
(en)
|
2016-07-15 |
2018-01-18 |
Etubics Corporation |
Compositions and methods for alphavirus vaccination
|
EP3484509A4
(en)
|
2016-07-15 |
2020-03-25 |
Etubics Corporation |
Compositions and methods for flavivirus vaccination
|
GB201614093D0
(en)
|
2016-08-17 |
2016-09-28 |
Autolus Ltd |
Vector
|
IL264439B1
(en)
|
2016-08-17 |
2024-04-01 |
Factor Bioscience Inc |
non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment
|
CA3034266A1
(en)
|
2016-08-19 |
2018-02-22 |
Brooklyn Immunotherapeutics Llc |
Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
|
EP3512875A2
(en)
|
2016-09-15 |
2019-07-24 |
Quadrucept Bio Limited |
Multimers, tetramers&octamers
|
JP2019531284A
(en)
|
2016-09-19 |
2019-10-31 |
セルジーン コーポレイション |
Methods of treating immune disorders using PD-1 binding proteins
|
WO2018053401A1
(en)
|
2016-09-19 |
2018-03-22 |
Celgene Corporation |
Methods of treating vitiligo using pd-1 binding proteins
|
AU2017331277A1
(en)
|
2016-09-23 |
2019-03-28 |
Marengo Therapeutics, Inc. |
Multispecific antibody molecules comprising lambda and kappa light chains
|
EP3519562A4
(en)
|
2016-09-29 |
2020-03-25 |
Nantkwest, Inc. |
Hla class i-deficient nk-92 cells with decreased immunogenicity
|
CA3041334A1
(en)
|
2016-11-08 |
2018-05-17 |
Delinia, Inc. |
Il-2 variants for the treatment of autoimmune diseases
|
US20190275133A1
(en)
|
2016-11-10 |
2019-09-12 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
US10011269B2
(en)
|
2016-11-30 |
2018-07-03 |
Ford Global Technologies, Llc |
Identifying in-range fuel pressure sensor error
|
BR122020025384B1
(en)
|
2016-12-13 |
2022-07-12 |
Delinia, Inc |
FUSION PROTEINS AND DIMERIC, USES OF THEM AND PHARMACEUTICAL COMPOSITION
|
EP3555125A4
(en)
|
2016-12-15 |
2019-11-20 |
The Brigham and Women's Hospital, Inc. |
Tissue-based biologics for the treatment of inflammatory and autoimmune disorders
|
WO2018119114A1
(en)
|
2016-12-22 |
2018-06-28 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
US10232053B2
(en)
|
2016-12-30 |
2019-03-19 |
Trieza Therapeutics, Inc. |
Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
|
US11065345B2
(en)
|
2017-01-04 |
2021-07-20 |
Nanotics, Llc |
Methods for assembling scavenging particles
|
WO2018129188A1
(en)
|
2017-01-04 |
2018-07-12 |
Nanotics, Llc |
Methods for assembling scavenging particles
|
US20200121719A1
(en)
|
2017-01-06 |
2020-04-23 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
CA3048907C
(en)
|
2017-01-06 |
2023-05-23 |
Nantkwest, Inc. |
Genetically modified nk-92 cells with decreased cd96/tigit expression
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
US10603358B2
(en)
|
2017-01-10 |
2020-03-31 |
Nodus Therapeutics |
Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator
|
US20200000862A1
(en)
|
2017-02-03 |
2020-01-02 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Oncolytic virus therapy
|
JP7200138B2
(en)
|
2017-02-16 |
2023-01-06 |
ソネット バイオセラピューティクス,インコーポレイテッド |
Albumin-binding domain fusion protein
|
EP3589303A4
(en)
|
2017-03-01 |
2020-11-25 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy
|
KR102619015B1
(en)
|
2017-03-15 |
2023-12-28 |
큐 바이오파마, 인크. |
How to Regulate Your Immune Response
|
CN110520436A
(en)
|
2017-03-15 |
2019-11-29 |
潘迪恩治疗公司 |
Target immunological tolerance
|
JOP20190224A1
(en)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
JP7148539B2
(en)
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
immunoconjugate
|
ES2928718T3
(en)
|
2017-04-03 |
2022-11-22 |
Hoffmann La Roche |
Immunoconjugates of an anti-PD-1 antibody with a mutant IL-2 or with IL-15
|
CN108686202A
(en)
|
2017-04-06 |
2018-10-23 |
张晋宇 |
tumour immunotherapy
|
TWI788340B
(en)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
Anti-icos agonist antibodies and uses thereof
|
KR20190136076A
(en)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
Interleukin-2 immunoconjugates, CD40 agonists and optional PD-1 axis binding antagonists for use in cancer treatment methods
|
BR112019023409A2
(en)
|
2017-05-10 |
2020-06-16 |
Iovance Biotherapeutics, Inc. |
METHODS FOR TREATING CANCER IN A PATIENT AND A HEMATOLOGICAL MALIGNITY, FOR EXPANDING TUMOR INFILTRANT LYMPHOCYTES, PERIPHERAL BLOOD LYMPHOCYTES AND INFILTRANT SPRAY LYMPHOCYTES, PROCEDURE FOR THE PREPARATION OF A POPULATION IN THE MANUFACTURE OF A POPULATION OF TUMOR INFILTRANT LYMPHOCYTES.
|
US11913962B2
(en)
|
2017-05-15 |
2024-02-27 |
University Of Miami |
Materials and methods for subjects at risk for viral reactivation
|
CN111107868A
(en)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
Antibody cytokine transplantation proteins and methods of use
|
JOP20190271A1
(en)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use for immune related disorders
|
US20200270334A1
(en)
|
2017-05-24 |
2020-08-27 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
US20210277085A1
(en)
|
2017-05-24 |
2021-09-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
JP2020521452A
(en)
|
2017-05-24 |
2020-07-27 |
パンディオン・セラピューティクス・インコーポレイテッド |
Targeted tolerance
|
EP3635097A1
(en)
|
2017-06-05 |
2020-04-15 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
WO2018227018A1
(en)
|
2017-06-07 |
2018-12-13 |
Silverback Therapeutics, Inc. |
Antibody conjugates of immune-modulatory compounds and uses thereof
|
MA49403A
(en)
|
2017-06-12 |
2021-03-24 |
Obsidian Therapeutics Inc |
PDE5 COMPOSITIONS AND IMMUNOTHERAPY METHODS
|
CN110719920B
(en)
|
2017-06-14 |
2024-01-30 |
苏州丁孚靶点生物技术有限公司 |
Protein heterodimers and uses thereof
|
CN111201035A
(en)
|
2017-06-19 |
2020-05-26 |
梅迪塞纳医疗股份有限公司 |
Uses and methods for IL-2 superagonists, agonists, and fusions thereof
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
CA3069017A1
(en)
|
2017-07-03 |
2019-01-10 |
Torque Therapeutics, Inc. |
Immunostimulatory fusion molecules and uses thereof
|
JP2020527025A
(en)
|
2017-07-12 |
2020-09-03 |
シンロジック オペレーティング カンパニー インコーポレイテッド |
Microorganisms programmed to produce immune modulators and anti-cancer therapeutic agents in tumor cells
|
US20190023760A1
(en)
|
2017-07-24 |
2019-01-24 |
Eth Zurich |
Method for preparing interleukin-2 or interleukin-2 analogues
|
US20200181220A1
(en)
|
2017-08-03 |
2020-06-11 |
Synthorx, Inc. |
Cytokine conjugates for the treatment of proliferative and infectious diseases
|
BR112020001944A2
(en)
|
2017-08-04 |
2020-08-04 |
Genmab A/S |
binding agent, nucleic acid, expression vector, cell, composition, methods for treating a disease and for producing a bispecific antibody, using a binding agent, and anti-idiotypic antibody.
|
CA3069930A1
(en)
|
2017-08-09 |
2019-02-14 |
Orionis Biosciences Inc. |
Cd8 binding agents
|
CA3069992A1
(en)
|
2017-08-09 |
2019-02-14 |
Orionis Biosciences Inc. |
Clec9a binding agents and use thereof
|
CN111328286A
(en)
|
2017-08-09 |
2020-06-23 |
奥里尼斯生物科学有限公司 |
PD-1 and PD-L1 binding agents
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to bcma and uses thereof
|
JP2021500852A
(en)
|
2017-08-18 |
2021-01-14 |
グリットストーン オンコロジー インコーポレイテッド |
Antigen-binding protein that targets shared antigens
|
US20210115453A1
(en)
|
2017-08-31 |
2021-04-22 |
Poseida Therapeutics, Inc. |
Transposon system and methods of use
|
TW201920247A
(en)
|
2017-09-07 |
2019-06-01 |
美商信號生物製藥公司 |
Antigen-presenting polypeptides and methods of use thereof
|
CA3074839A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
|
BR112020004535A2
(en)
|
2017-09-07 |
2020-09-08 |
Cue Biopharma, Inc. |
multimeric t cell modulating peptides and methods of using these
|
TW201925235A
(en)
|
2017-09-07 |
2019-07-01 |
美商信號生物製藥公司 |
Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
|
WO2019051424A2
(en)
|
2017-09-08 |
2019-03-14 |
Poseida Therapeutics, Inc. |
Compositions and methods for chimeric ligand receptor (clr)-mediated conditional gene expression
|
AU2018338608A1
(en)
|
2017-09-27 |
2020-04-09 |
Sigilon Therapeutics, Inc. |
Methods, compositions, and implantable elements comprising active cells
|
CN117430699A
(en)
|
2017-09-30 |
2024-01-23 |
合肥立方制药股份有限公司 |
Proteins binding to fibronectin B domain
|
US11474271B2
(en)
|
2017-10-24 |
2022-10-18 |
Schlumberger Technology Corporation |
Methods and systems for automated sonic imaging
|
WO2019084284A1
(en)
|
2017-10-27 |
2019-05-02 |
Coneksis, Inc. |
Nk cells for use in treating cancer in canines
|
CA3081539A1
(en)
|
2017-11-08 |
2019-05-16 |
Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. |
Conjugates of biomolecule and use thereof
|
WO2019092504A1
(en)
|
2017-11-13 |
2019-05-16 |
Extremochem, Lda. |
Neutral glycosylated amides and dianionic glucuronidated acids as stabilizers for biological molecules
|
BR112020009663A2
(en)
|
2017-11-17 |
2020-11-10 |
Iovance Biotherapeutics, Inc. |
method for the expansion of tumor infiltrating lymphocytes (tils) in a therapeutic population of tils, method for the treatment of an individual with cancer, composition
|
AU2018372167B2
(en)
|
2017-11-21 |
2023-12-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Partial agonists of interleukin-2
|
JP2021503885A
(en)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Expanded culture of peripheral blood lymphocytes (PBL) from peripheral blood
|
SG11202003965VA
(en)
|
2017-12-06 |
2020-06-29 |
Pandion Therapeutics Inc |
Il-2 muteins and uses thereof
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
WO2019113221A1
(en)
|
2017-12-06 |
2019-06-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Engineered proteins to enhance sensitivity of a cell to il-2
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
JP2021505156A
(en)
|
2017-12-06 |
2021-02-18 |
パンディオン・オペレーションズ・インコーポレイテッド |
Targeted immune tolerance
|
US20190175651A1
(en)
|
2017-12-13 |
2019-06-13 |
Janssen Biotech, Inc. |
Immortalized car-t cells genetically modified to elminate t-cell receptor and beta 2-microglobulin expression
|
JP2021508104A
(en)
|
2017-12-15 |
2021-02-25 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Systems and methods for determining beneficial administration of tumor-infiltrating lymphocytes and their use, as well as beneficial administration of tumor-infiltrating lymphocytes and their use.
|
MX2020006322A
(en)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Engineered il-2 fc fusion proteins.
|
EP3502139A1
(en)
|
2017-12-19 |
2019-06-26 |
Philogen S.p.A. |
Antibodies to tumour antigens
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
US11629189B2
(en)
|
2017-12-19 |
2023-04-18 |
Kymab Limited |
Bispecific antibody for ICOS and PD-L1
|
JP2021507703A
(en)
|
2017-12-20 |
2021-02-25 |
ポセイダ セラピューティクス,インコーポレイティド |
VCAR composition and its usage
|
EP3733716A4
(en)
|
2017-12-26 |
2021-11-24 |
Nanjing GenScript Biotech Co., Ltd. |
Fusion protein dimer using antibody fc region as backbone and use thereof
|
US20210060169A1
(en)
|
2017-12-27 |
2021-03-04 |
Kyowa Kirin Co., Ltd. |
Il-2 variant
|
EP3732197A1
(en)
|
2017-12-28 |
2020-11-04 |
Julius-Maximilians-Universität Würzburg |
TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCyR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCyR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
CA3087771A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
CN111886241A
(en)
|
2018-01-09 |
2020-11-03 |
库尔生物制药有限公司 |
Multimeric T cell modulating polypeptides and methods of use thereof
|
JP2021511348A
(en)
|
2018-01-24 |
2021-05-06 |
ベイジン パーカンズ オンコロジー カンパニー リミテッド |
Cytokine fusion protein
|
WO2019144309A1
(en)
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine Fusion Proteins
|
AR114127A1
(en)
|
2018-03-02 |
2020-07-22 |
Lilly Co Eli |
AGONIST ANTIBODIES AGAINST PD-1 AND USES OF THEM
|
MX2020009309A
(en)
|
2018-03-07 |
2021-01-08 |
Poseida Therapeutics Inc |
Cartyrin compositions and methods for use.
|
CN113166220A
(en)
|
2018-03-09 |
2021-07-23 |
奥美药业有限公司 |
Novel cytokine prodrugs
|
EP3820499A4
(en)
|
2018-07-09 |
2022-07-13 |
Surrozen Operating, Inc. |
Tissue-specific wnt signal enhancing molecules and uses
|
KR20210038549A
(en)
|
2018-07-24 |
2021-04-07 |
비온테크 알엔에이 파마슈티컬스 게엠베하 |
IL2 agonist
|
WO2020061142A1
(en)
|
2018-09-18 |
2020-03-26 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
US20220106398A1
(en)
|
2019-02-08 |
2022-04-07 |
Igm Biosciences, Inc. |
Anti-gitr antigen-binding domains and uses thereof
|
BR112021023345A2
(en)
|
2019-05-20 |
2022-02-01 |
Pandion Operations Inc |
Targeted immunotolerance in madcam
|
US11095944B2
(en)
|
2019-08-19 |
2021-08-17 |
Roku, Inc. |
Content-modification system with broadcast schedule utilization feature
|
EP4017595A4
(en)
|
2019-08-19 |
2023-12-20 |
Pandion Operations, Inc. |
Targeted immunotolerance with a pd-1 agonist
|
US20230235004A1
(en)
|
2020-02-21 |
2023-07-27 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with pd-1 agonists or il-2 muteins
|
US20210269496A1
(en)
|
2020-02-21 |
2021-09-02 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a cd39 effector
|
MX2023002045A
(en)
|
2020-08-19 |
2023-05-08 |
Pandion Operations Inc |
Multi-paratopic anti-pd-1 antibodies and uses thereof.
|
WO2022082019A2
(en)
|
2020-10-16 |
2022-04-21 |
Pandion Operations, Inc. |
Kidney targeted immunotolerance
|
EP4229078A2
(en)
|
2020-10-16 |
2023-08-23 |
Pandion Operations, Inc. |
Skin targeted immunotolerance
|